Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...

Explore why Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams.

Abcuro appointed former Priovant Therapeutics exec Courtney Cupples as chief commercial officer. Innospera Pharma appointed ...

Blueprint specializes in systemic mastocytosis, a rare immunological disease, and other Kit-driven diseases. With this ...

STOCKHOLM--Swedish buyout group EQT and French pharmaceutical major Sanofi co-led a $135 million series B financing round in Spanish biotech company SpliceBio. EQT co-led the funding round with Sanofi ...

Spain’s SpliceBio will use $135 million from a series B round backed by Sanofi and Roche to advance its lead gene editing ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

In an effort to greater prepare HCPs and to avoid potential shortages, the company targets Q3 as the shipment date.

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...